Agile Development of a Digital Exposure Treatment for Youth With Chronic Musculoskeletal Pain

Sponsor
Stanford University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05079984
Collaborator
Karolinska Institutet (Other), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (NIH)
70
1
1
48
1.5

Study Details

Study Description

Brief Summary

This project proposes to systematically develop and evaluate the feasibility and preliminary effectiveness of a digitally delivered, graded exposure treatment for youth with chronic musculoskeletal pain, utilizing a sequential replicated and randomized single-case experimental design (SCED). SCED provides the opportunity to rigorously evaluate treatment effectiveness at the individual level.

Development of iGET Living will be based on a series of short iterations, with alpha testing (Aim 1) on a small sample of adolescents with chronic pain (N = 15) and their parents (N = 15). For Aim 1, participants will participate in three, two hour focus groups (one per week over the course of three weeks), resulting in 6 total hours of participation per participant for Aim 1.

Aim 2 will involve a sample (N = 20 youth, N = 20 parents) of naïve end-users. Participants will be enrolled in a baseline period ranging from 7-25 days (done to support SCED methodology) after which they will be enrolled in the online intervention program, lasting 6-weeks. Patients will be contacted 3-months post-discharge from treatment (week 22 of enrollment) and will complete self-report outcome measures at this time.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Graded exposure treatment (GET)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
N/A
Intervention Model:
Sequential Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Agile Development of a Digital Exposure Treatment for Youth With Chronic Musculoskeletal Pain
Actual Study Start Date :
May 2, 2022
Anticipated Primary Completion Date :
Mar 1, 2025
Anticipated Study Completion Date :
May 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Graded Exposure Intervention

For Aim 2, adolescents with chronic pain will be enrolled in a single-arm feasibility trial examining acceptability, feasibility, and preliminary effectiveness of a novel, digitally delivered, graded exposure treatment.

Behavioral: Graded exposure treatment (GET)
Graded-exposure is a theory driven, individually tailored, and evidenced based behavioral intervention for individuals with chronic pain targeting pain-related impairment by exposing patients to previously feared and avoided activities.

Outcome Measures

Primary Outcome Measures

  1. Assessment of Acceptability of Treatment Content and Digital Delivery Questionnaire - Likert Scale (Aim 1 and Aim 2) [Baseline through 3-month follow-up (up to 22 weeks)]

    Participant-rated acceptability measured on 5-point Likert scale. Range 0-4 (higher scores indicate more acceptable). Questionnaire will be administered to youth with chronic pain and their parents.

  2. Assessment of Acceptability of Treatment Content and Digital Delivery Questionnaire - Participant Responses (Aim 1 and Aim 2) [Baseline through 3-month follow-up (up to 22 weeks)]

    Acceptability will be assessed qualitatively through participant responses to open-ended questions related to acceptability, ease of use, comprehensibility, and suggestions for improvement. Responses will be assessed categorically by the investigator. Questionnaire will be administered to youth with chronic pain and their parents.

  3. Participant Satisfaction with the Intervention (Aim 1 and Aim 2) [19 weeks (Assessed at the end of treatment)]

    Treatment satisfaction at the end of treatment will be evaluated by examining mean satisfaction scores on an adapted version of the Pain Service Satisfaction Test (PSST, McCracken et al., 1997). The PSST consists of 23 items rated on a 5-point Likert Scale (0 = not at all satisfied to 4 = very satisfied) and assesses the patient and parent's experience of the intervention. Scores range from 0-92. A score greater than/equal to 40 of 60 (satisfied to very satisfied) will indicate high levels of satisfaction with the intervention content.

  4. Percentage of Participants Dropped Out of Intervention (Aim 2) [19 weeks (Assessed at the end of treatment)]

    As a measure of treatment adherence, we will calculate the percentage of participants who drop out or withdraw from the intervention prior to completion of the intervention.

  5. Expectations for Treatment (Aim 2) [Baseline (up to 2 minutes to complete the survey)]

    Participants (child) and parent expectations for treatment will be measured by the Treatment Expectancy and Creditability, Borkovec & Nau, 1972). The TEC is comprised of 6 items rated on a 0 to 10 Likert-scale assessing expectations related to the effectiveness of the current treatment. The TEC is completed by the patient at the end of the first treatment session. Higher scores indicate greater expectations for treatment effectiveness.

  6. Functional Disability (Aim 2) [Baseline through 3-month follow-up (up to 22 weeks)]

    Functional disability will be assessed using the Functional Disability Inventory (FDI, Walker & Greene, 1991), a 15-item self-report measure of perceived difficulty in performing activities in school, home, physical, and social contexts. Items are rated on a 5-point Likert scale ranging from 0 (no trouble) to 4 (impossible). Items are summed to create a total score (range 0-60), with higher scores indicating greater disability.

Secondary Outcome Measures

  1. Child Fear of Pain (Aim 2) [Baseline through 3-month follow-up (up to 22 weeks)]

    Fear of Pain Questionnaire- Child (FOPQ-C, Simons et al., 2011) consists of 24 items, with each item rated on a 5-point Likert scale (0 = "strongly disagree" to 4 = "strongly agree"). The FOPQ-C contains two subscales: Fear of Pain (11 items) and Avoidance of Activities (13 items). Total score is derived by summing subscale items, with higher scores indicating greater pain related fear (score range 0-44) and avoidance of activities (score range 0-52).

  2. Parental Fear of Pain (Aim 2) [Baseline through 3-month follow-up (up to 22 weeks)]

    The Parent Fear of Pain Questionnaire (PFOPQ, Simons et al., 2015) assesses parent's fear associated with their child's pain experiences. The PFOPQ contains 23 items assessed on a 5-point Likert scale (0 = "strongly disagree" to 4 "strongly agree"). Items are summed to create a total score (0-92), with higher scores indicated greater parent fear associated with their child's pain.

  3. Child Pain Catastrophizing (Aim 2) [Baseline through 3-month follow-up (up to 22 weeks)]

    The Pain Catastrophizing Scale -Child Version (PCS-C, Crombez et al., 2003) assesses negative cognitions associated with pain. The PCS-C is comprised of 13-items rated on a 5-point Likert scale (0= "not at all true" to 4 "very true"). A total score (0-52) is obtained by summing all items. Higher scores indicate higher levels of catastrophic thinking.

  4. Parent Pain Catastrophizing (Aim 2) [Baseline through 3-month follow-up (up to 22 weeks)]

    Pain Catastrophizing Scale-Parent Version (PCS-P, Goubert et al., 2006) assesses parents' negative cognitions associated with their child's pain. It is comprised of 13 items rated on a 5-point Likert scale (0 = "not true at all" to 4 = "very true"). A total score (0-52) is derived by summing items, with higher scores indicating higher levels of catastrophic thinking.

  5. Child Pain Acceptance (Aim 2) [Baseline through 3-month follow-up (up to 22 weeks)]

    Child report on the Chronic Pain Acceptance Questionnaire for Adolescents-short form (CPAQ-A8, Gauntlett-Gilbert et al., 2018) will be used to assess pain acceptance in the child. The CPAQ-A8 is an 8-item measure consisting of two subscales: Activity Engagement (4 items) and Pain Willingness (4 items). Items are rated on a 5-point Likert scale ranging from 0 (Never True) to 4 (Always True) and yield a total score for each subscale ranging from 0-16. Higher scores indicate greater Activity Engagement and greater Pain Willingness .

  6. Parent Psychological Flexibility (Aim 2) [Baseline through 3-month follow-up (up to 22 weeks)]

    The Parent Psychological Flexibility Questionnaire (PPFQ-10, Timmers et al., 2019) is a 10-item parent self-report questionnaire assessing a parent's ability to accept their own distress and respond adaptively and flexibly to their child's pain. Items are rated on a 5-point Likert scale (0= " never true" to 4 = "always true") and are summed to create a total score, ranging from 0 - 40. Higher scores indicate greater parent psychological flexibility.

  7. Parent Responses to Childs Pain (Aim 2) [Baseline through 3-month follow-up (up to 22 weeks)]

    Adult Responses to Children's Symptoms (ARCS, Claar et al., 2010) assesses parents' behavioral responses to children's pain behaviors. The Protect subscale (13 items) will be utilized in this study. The Protect scale refers to protective parental behavior, such as giving the child special attention and limiting the child's normal activities and responsibilities. All items are rated on a 5-point Likert scale (0 = "never" to 4 "always"), and are averaged to create a total score ranging from 0-4. Hiigher scores indicating greater use of a particular type of response to their child's pain.

Eligibility Criteria

Criteria

Ages Eligible for Study:
10 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Youth ages 10-17

  • Have diagnosis of chronic musculoskeletal pain (>3months)

  • Have moderate to high pain interference (PROMIS Pain Interference ≥ 61)

  • English literate

  • Have access to computer, smartphone, or tablet with internet connection

Exclusion Criteria:
  • Significant cognitive impairment (e.g., brain injury)

  • Significant medical or psychiatric problems that would interfere with treatment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Pediatric Pain Management Clinic Menlo Park California United States 94025

Sponsors and Collaborators

  • Stanford University
  • Karolinska Institutet
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Investigators

  • Principal Investigator: Lauren E Harrison, PhD, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Lauren Harrison, Clinical Instructor, Stanford University
ClinicalTrials.gov Identifier:
NCT05079984
Other Study ID Numbers:
  • 53323
  • 1K23AR079608-01
First Posted:
Oct 15, 2021
Last Update Posted:
Aug 1, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 1, 2022